APDN Applied DNA Sciences
- 1.990
- -0.040-1.97%
- 2.000
- +0.010+0.50%
Applied DNA Sciences News
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increas
Maxim Downgrades Applied DNA Sciences to Hold From Buy
Maxim Downgrades Applied DNA Sciences to Hold From Buy.
Applied DNA Sciences Is Maintained at Buy by HC Wainwright & Co.
Applied DNA Sciences Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Applied DNA Sciences, Adjusts Price Target To $7
HC Wainwright & Co. analyst Yi Chen maintains Applied DNA Sciences (NASDAQ:APDN) with a Buy, adjusts target to $7 from $1.5.
HC Wainwright & Co. : Maintaining the Applied DNA Sciences (APDN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $1.50 to $7.00.
HC Wainwright & Co. : Maintaining the Applied DNA Sciences (APDN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $1.50 to $7.00.
Applied DNA Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 159.84% HC Wainwright & Co. $1.5 → $7 Maintains Buy 02/09/2024 -44.32% HC Wainwright & Co. $2 →
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚH
Top Premarket Decliners
Barnes & Noble Education (BNED) shares were down nearly 35% in recent Monday premarket activity, extending Friday's 7.4% loss. Seritage Growth Properties (SRG) stock was 28% lower, extending Friday's
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
Applied DNA Sciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Financial Results.
Applied DNA Sciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Financial Results.
Applied DNA Sciences Poised for Growth With Strategic Alliances and Revenue Uptick: A Buy Rating
Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Shares of JanOne Inc. (NASDAQ:JAN) rose sharply in today's pre-market trading after the company announced plans to acquire ALT 5 Sigma Inc.The deal is projected to close in the week of May 13th.JanOne
Applied DNA Sciences Second Quarter 2024 Earnings: Misses Expectations
Applied DNA Sciences (APDN.US): The 2024 Q2 earnings report achieved revenue of $929,63 million, with a previous value of $4.408 million and an expected value of $950,000; earnings per share were -2.71 dollars, previous value of -0.20 dollars, and expecte
Applied DNA Sciences (APDN.US): The 2024 Q2 earnings report achieved revenue of $929,63 million, with a previous value of $4.408 million and an expected value of $950,000; earnings per share were -2.71 dollars, previous value of -0.20 dollars, and expected value of -4.50 dollars.
Applied DNA Sciences Q2 EPS $(5.31) Misses $(4.50) Estimate, Sales $929.63K Miss $950.00K Estimate
Applied DNA Sciences (NASDAQ:APDN) reported quarterly losses of $(5.31) per share which missed the analyst consensus estimate of $(4.50) by 18 percent. This is a 2555 percent decrease over losses of $
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q2 Revenue $929,631
04:07 PM EDT, 05/10/2024 (MT Newswires) -- Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q2 Revenue $929,631
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. , a leader in PCR-based DNA technologies, today announced consolidated financial
10-Q: Quarterly report
Applied DNA Sciences Shares Resume Trade Following Circuit Breaker Halt
Applied DNA Sciences Shares Resume Trade Following Circuit Breaker Halt
Applied DNA Regains Compliance With Nasdaq Minimum Bid Price Requirement
Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
Analysis
Price Target
No Data
